Vaxcyte

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering, Ashish Khanna and Jeff Fairman on November 27, 2013 and is headquartered in San Carlos, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vaxcyte reports robust Q4 performance and eyes vaccine market growth

Vaxcyte's Q4 performance highlighted strong financials, promising pipeline programs, and strategic market positioning.
The company faces challenges in pediatric efficacy translation, differentiation, and operational scalability.
Opportunities lie in expanding manufacturing, leveraging unique vaccine approaches, and addressing critical medical needs.

Vaxcyte excels in 2023 with strong PCV progress and financial growth

Vaxcyte's strong performance in 2023, with progress in key PCV candidates and financial strength, positions them well in the competitive vaccine market. Challenges include uncertainties in the competitive landscape and adapting to different vaccination schedules globally. Opportunities lie in upcoming milestones, global commercialization, and meeting the demand for broadly protective vaccines.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.

-- Company Expects to Announce Topline Results from the Phase 1/2 Study   by the End of 2022 -- -- Proof-of-Concept Study Will Evaluate the Safety, Tolerability and Immunogenicity of VAX-24 --

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

SAN CARLOS, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that it will report financial results for the fourth quarter and full year 2021 after market close on February 28, 2022. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update.

Vaxcyte to Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022

SAN CARLOS, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will present at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 2:20 p.m. ET / 11:20 a.m. PT.

Vaxcyte to Present at the 11th Annual SVB Leerink Global Healthcare Conference

The stock price of Vaxcyte Inc (NASDAQ: PCVX) fell by 9.5% in the most recent trading session. This is why it happened.

Vaxcyte Stock (PCVX): Why The Price Went Down

Vaxcyte Inc (NASDAQ: PCVX) priced its previously announced offering of common stock and pre-funded warrants at $20.00 per share, and $19.999 per underlying share, respectively. Vaxcyte is selling 2.5 million shares and pre-funded warrants to purchase 2.5 million shares of common stock in the offering.

Vaxcyte Raises $100M Via Equity To Fund Development Of Lead Pneumococcal Vaccine Candidate

SAN CARLOS, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 2,500,000 shares of common stock and pre-funded warrants to purchase 2,500,000 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $20.00 per share, and the pre-funded warrants are being sold at a public offering price of $19.999 per underlying share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be approximately $100.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock at the public offering price per share.

Vaxcyte Announces Pricing of $100 Million Public Offering

SAN CARLOS, Calif., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it has commenced an underwritten public offering of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering (including shares underlying the pre-funded warrants). The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Vaxcyte Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

-- Company Expects to Deliver Topline Immunogenicity Results from the Phase 1/2 Clinical Study by End of 2022 -- -- VAX-24 is a 24-Valent Pneumococcal Conjugate Vaccine Candidate Designed to Provide Broad-Spectrum Protection --

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease

The average of price targets set by Wall Street analysts indicates a potential upside of 96.5% in Vaxcyte, Inc. (PCVX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Vaxcyte, Inc. (PCVX) Could Surge 96%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 89% in Vaxcyte (PCVX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Vaxcyte (PCVX) Have the Potential to Rally 89% as Wall Street Analysts Expect?

-- Company Expects to Submit VAX-24 IND Application to FDA in Q1 2022 -- -- Completed Manufacture of VAX-24 GMP Drug Product and GLP Toxicology Study --

Vaxcyte Reports Third Quarter 2021 Financial Results and Provides Business Update

FOSTER CITY, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced it has appointed Carlos Paya and Michael Kamarck, accomplished industry leaders, to its board of directors. Dr. Paya will also serve as the Board Chair. Kurt von Emster, a longtime director who served as Interim Chair, will remain on the board.

Vaxcyte Appoints Carlos Paya and Michael Kamarck to Its Board of Directors

FOSTER CITY, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that Company management will participate in a fireside chat at the Guggenheim 2nd Annual Vaccine and Infectious Disease Conference on Tuesday, October 5, 2021 at 11:30am ET.

Vaxcyte to Present at Guggenheim 2nd Annual Vaccine and Infectious Disease Conference

FOSTER CITY, Calif., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that Company management will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 8:40am ET.

Vaxcyte to Present at 2021 Cantor Virtual Global Healthcare Conference

FOSTER CITY, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced it has appointed Annie Drapeau and Teri Loxam to its board of directors. In connection with these appointments, longtime board members Patrick Heron and Rob Hopfner have stepped down from the board.

Vaxcyte Appoints Annie Drapeau and Teri Loxam to Its Board of Directors

FOSTER CITY, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced financial results for the second quarter ended June 30, 2021 and provided a business update.

Vaxcyte Reports Second Quarter 2021 Financial Results and Provides Business Update

Apple

Caterpillar

Salesforce

Cisco Systems

Goldman Sachs

Home Depot

Intel

McDonald's

Merck

Microsoft

Sio Gene Therapies

UnitedHealth Group

Visa

Two new sample breakout stocks for Week 26 with better than 10% short-term upside potential. This past week, the peak gains were in PDSB +18.6% and FSTX +6.7% with Market and S&P 500 Momentum Gauges the most negative since February.

Week 26 MDA Breakout Stocks - July 2021: Short-Term Picks To Give You An Edge

FOSTER CITY, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that Company management will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 4:00pm ET.

Vaxcyte to Present at the Jefferies Virtual Healthcare Conference

FOSTER CITY, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced financial results for the first quarter ended March 31, 2021 and provided a business update.

Vaxcyte Reports First Quarter 2021 Financial Results and Provides Business Update

VAX-24 is a 24-Valent Broad-Spectrum Pneumococcal Conjugate Vaccine Leveraging Vaxcyte's Technology Platform VAX-24 is a 24-Valent Broad-Spectrum Pneumococcal Conjugate Vaccine Leveraging Vaxcyte's Technology Platform

Vaxcyte Announces Publication of Preclinical Data Supporting the Potential of VAX-24 for the Prevention of Invasive Pneumococcal Disease

FOSTER CITY, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that company management will participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021 at 1:30 p.m. ET.

Vaxcyte to Present at 20th Annual Needham Virtual Healthcare Conference

Vaxcyte, Inc. (PCVX) CEO Grant Pickering on Q4 2020 Results - Earnings Call Transcript

FOSTER CITY, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided a business update.

Vaxcyte Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

U.S. vaccine developer Vaxcyte Inc on Thursday asked board chairman Moncef Slaoui to step down, a day after GlaxoSmithKline dismissed him as an independent probe found he had sexually harassed a GSK employee several years ago.

Vaxcyte asks chairman Slaoui to resign after GSK harassment allegation

FOSTER CITY, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that it will report financial results for the fourth quarter and full year 2020 after market close on March 29, 2021. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update.

News for Vaxcyte Stock (PCVX)